Cargando…

Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease

INTRODUCTION: Patients suffering from Sickle Cell Disease (SCD) are at increased risk for complications due to influenza virus. Annual influenza vaccination is strongly recommended but few clinical studies have assessed its immunogenicity in individuals with SCD. The aim of this study was to explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagant, Carole, Barbezange, Cyril, Dedeken, Laurence, Besse-Hammer, Tatiana, Thomas, Isabelle, Mahadeb, Bhavna, Efira, André, Ferster, Alice, Corazza, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786629/
https://www.ncbi.nlm.nih.gov/pubmed/31600331
http://dx.doi.org/10.1371/journal.pone.0223991
_version_ 1783458103499423744
author Nagant, Carole
Barbezange, Cyril
Dedeken, Laurence
Besse-Hammer, Tatiana
Thomas, Isabelle
Mahadeb, Bhavna
Efira, André
Ferster, Alice
Corazza, Francis
author_facet Nagant, Carole
Barbezange, Cyril
Dedeken, Laurence
Besse-Hammer, Tatiana
Thomas, Isabelle
Mahadeb, Bhavna
Efira, André
Ferster, Alice
Corazza, Francis
author_sort Nagant, Carole
collection PubMed
description INTRODUCTION: Patients suffering from Sickle Cell Disease (SCD) are at increased risk for complications due to influenza virus. Annual influenza vaccination is strongly recommended but few clinical studies have assessed its immunogenicity in individuals with SCD. The aim of this study was to explore the biological efficacy of annual influenza vaccination in SCD patients by characterizing both their humoral and cell-mediated immunity against influenza antigen. We also aimed to investigate these immunological responses among SCD individuals according to their treatment (hydroxyurea (HU), chronic blood transfusions (CT), both HU and CT or none of them). METHODS: Seventy-two SCD patients (49 receiving HU, 9 on CT, 7 with both and 7 without treatment) and 30 healthy controls were included in the study. All subjects received the tetravalent influenza α-RIX-Tetra® vaccine from the 2016–2017 or 2017–2018 season. RESULTS: Protective anti-influenza HAI titers were obtained for the majority of SCD patients one month after vaccination but seroconversion rates in patient groups were strongly decreased compared to controls. Immune cell counts, particularly cellular memory including memory T and memory B cells, were greatly reduced in SCD individuals. Functional activation assays confirmed a poorer CD8(+) T cell memory. We also document an imbalance of cytokines after influenza vaccination in SCD individuals with an INFγ/IL-10 ratio (Th1-type/Treg-type response) significantly lower in the SCD cohort. CONCLUSION: SCD patients undergoing CT showed altered immune regulation as compared to other treatment subgroups. Altogether, the cytokine imbalance, the high regulatory T cell levels and the low memory lymphocyte subset levels observed in the SCD cohort, namely for those on CT, suggest a poor ability of SCD patients to fight against influenza infection. Nevertheless, our serological data support current clinical practice for annual influenza vaccination, though immunogenicity to other vaccines involving immunological memory might be hampered in SCD patients and should be further investigated.
format Online
Article
Text
id pubmed-6786629
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-67866292019-10-19 Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease Nagant, Carole Barbezange, Cyril Dedeken, Laurence Besse-Hammer, Tatiana Thomas, Isabelle Mahadeb, Bhavna Efira, André Ferster, Alice Corazza, Francis PLoS One Research Article INTRODUCTION: Patients suffering from Sickle Cell Disease (SCD) are at increased risk for complications due to influenza virus. Annual influenza vaccination is strongly recommended but few clinical studies have assessed its immunogenicity in individuals with SCD. The aim of this study was to explore the biological efficacy of annual influenza vaccination in SCD patients by characterizing both their humoral and cell-mediated immunity against influenza antigen. We also aimed to investigate these immunological responses among SCD individuals according to their treatment (hydroxyurea (HU), chronic blood transfusions (CT), both HU and CT or none of them). METHODS: Seventy-two SCD patients (49 receiving HU, 9 on CT, 7 with both and 7 without treatment) and 30 healthy controls were included in the study. All subjects received the tetravalent influenza α-RIX-Tetra® vaccine from the 2016–2017 or 2017–2018 season. RESULTS: Protective anti-influenza HAI titers were obtained for the majority of SCD patients one month after vaccination but seroconversion rates in patient groups were strongly decreased compared to controls. Immune cell counts, particularly cellular memory including memory T and memory B cells, were greatly reduced in SCD individuals. Functional activation assays confirmed a poorer CD8(+) T cell memory. We also document an imbalance of cytokines after influenza vaccination in SCD individuals with an INFγ/IL-10 ratio (Th1-type/Treg-type response) significantly lower in the SCD cohort. CONCLUSION: SCD patients undergoing CT showed altered immune regulation as compared to other treatment subgroups. Altogether, the cytokine imbalance, the high regulatory T cell levels and the low memory lymphocyte subset levels observed in the SCD cohort, namely for those on CT, suggest a poor ability of SCD patients to fight against influenza infection. Nevertheless, our serological data support current clinical practice for annual influenza vaccination, though immunogenicity to other vaccines involving immunological memory might be hampered in SCD patients and should be further investigated. Public Library of Science 2019-10-10 /pmc/articles/PMC6786629/ /pubmed/31600331 http://dx.doi.org/10.1371/journal.pone.0223991 Text en © 2019 Nagant et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Nagant, Carole
Barbezange, Cyril
Dedeken, Laurence
Besse-Hammer, Tatiana
Thomas, Isabelle
Mahadeb, Bhavna
Efira, André
Ferster, Alice
Corazza, Francis
Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease
title Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease
title_full Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease
title_fullStr Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease
title_full_unstemmed Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease
title_short Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease
title_sort alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with sickle cell disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786629/
https://www.ncbi.nlm.nih.gov/pubmed/31600331
http://dx.doi.org/10.1371/journal.pone.0223991
work_keys_str_mv AT nagantcarole alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease
AT barbezangecyril alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease
AT dedekenlaurence alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease
AT bessehammertatiana alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease
AT thomasisabelle alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease
AT mahadebbhavna alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease
AT efiraandre alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease
AT fersteralice alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease
AT corazzafrancis alterationofhumoralcellularandcytokineimmuneresponsetoinactivatedinfluenzavaccineinpatientswithsicklecelldisease